GlobeNewswire

Northland Power Adds 17MW of Capacity to the Deutsche Bucht Offshore Wind Farm

Dela

TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) announced today that the Deutsche Bucht Mono Bucket pilot demonstrator ("Demo") project has reached financial close.  All required funds for the Demo project have been contributed by Northland and committed by the project lenders.

In May, the Federal Maritime and Hydrographic Agency of Germany (BSH) granted the Deutsche Bucht offshore wind project the permit required to erect two additional pilot wind turbines using Mono Bucket foundations. Deutsche Bucht will be the first offshore wind farm worldwide to test this new type of foundation structure under commercial operating conditions. As previously announced, the two turbines will contribute an additional 17 MW of capacity to the base 252 MW project for a total of 269 MW and bringing the total project cost to approximately €1.4 billion (CAD $2.0 billion) - up from €1.3 billion. Northland's corporate investment has increased from approximately $400 million to approximately $430 million, funded by cash on hand. The balance of the Demo project cost will be funded with non-recourse project finance debt and pre-completion revenues.  Production from the additional 17 MW Demo project will earn the same fixed feed-in tariff subsidy for approximately 13 years under the German Renewable Energy Act ("EEG") as the base project, equating to approximately €184/MWh for 8 years and €149/MWh for the remainder.  The Demo project is expected to be accretive to the base project since it will share the base project's infrastructure.   Inclusive of the additional 17 MW from the Demo project, Northland owns 100% of the 269 MW offshore wind farm, which will be located in the German North Sea.

John Brace, CEO of Northland Power, said: "Today's announcement represents yet another first for Northland Power. The addition of the Demo turbines is not only innovative and accretive to the base project, but we are able to undertake this initiative with little additional risk since they will be integrated into the overall construction project. The innovative new mono bucket design could be of significant benefit to some of Northland's future offshore wind farms. The learnings from this pilot could allow Northland to construct faster and lower costs for certain site conditions."

The Deutsche Bucht project is currently under construction, with completion anticipated in the second half of 2019.

ABOUT NORTHLAND

Northland is an independent power producer founded in 1987, and publicly traded since 1997. Northland develops, builds, owns and operates facilities that produce 'clean' (natural gas) and 'green' (wind, solar, and hydro) energy, providing sustainable long-term value to shareholders, stakeholders, and host communities.

The Company owns or has an economic interest in 2,458 MW (net 2,029 MW) of operating generating capacity and 269 MW of generating capacity under construction - the Deutsche Bucht offshore project in the North Sea, in addition to its 60% equity stake in the 1,044 MW Hai Long projects that hold grid allocation rights.

Northland's common shares, Series 1, Series 2 and Series 3 preferred shares and Series B and Series C convertible debentures trade on the Toronto Stock Exchange under the symbols NPI, NPI.PR.A, NPI.PR.B, NPI.PR.C, NPI.DB.B, and NPI.DB.C, respectively.

FORWARD LOOKING STATEMENTS

This release contains certain forward-looking statements which are provided for the purpose of presenting information about management's current expectations and plans.  Readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as "expects," "anticipates," "plans," "believes," "estimates," "intends," "targets," "projects," "forecasts" or negative versions thereof and other similar expressions, or future or conditional verbs such as "may," "will," "should," "would" and "could." These statements may include, without limitation, statements regarding future adjusted EBITDA, free cash flows, dividend payment and dividend payout ratios, the construction, completion, attainment of commercial operations, cost and output of development projects, litigation claims, plans for raising capital, and the operations, business, financial condition, priorities, ongoing objectives, strategies and outlook of Northland and its subsidiaries.  These statements are based upon certain material factors or assumptions that were applied in developing the forward-looking statements, including the design specifications of development projects, the provisions of contracts to which Northland or a subsidiary is a party, management's current plans, its perception of historical trends, current conditions and expected future developments, as well as other factors that are believed to be appropriate in the circumstances.  Although these forward-looking statements are based upon management's current reasonable expectations and assumptions, they are subject to numerous risks and uncertainties. Some of the factors that could cause results or events to differ from current expectations include, but are not limited to, construction risks, counterparty risks, operational risks, foreign exchange rates, regulatory risks, maritime risks for construction and operation, and the variability of revenues from generating facilities powered by intermittent renewable resources and the other factors described in the "Risks and Uncertainties" section of Northland's 2016 Annual Report and Annual Information Form, both of which can be found at  www.sedar.com  under Northland's profile and on Northland's website  www.northlandpower.ca . Northland's actual results could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur.

The forward-looking statements contained in this release are based on assumptions that were considered reasonable on date of release.  Other than as specifically required by law, Northland undertakes no obligation to update any forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

For further information:
Contact Barb Bokla, Manager, Investor Relations, 647-288-1438
Or Sarah Charuk, Director of Communications, 647-288-1105
E-Mail:                    investorrelations@northlandpower.com
Website: www.northlandpower.ca




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Northland Power Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum